Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

3.98

Today's Change

-0.24 (5.68%)

Day's Change

3.82 - 4.18

Trading Volume

1,661,755

Overview

Market Cap

1 Billion

Shares Outstanding

320 Million

Avg Volume

1,642,806

Avg Price (50 Days)

5.55

Avg Price (200 Days)

5.60

PE Ratio

-26.53

EPS

-0.15

Earnings Announcement

26-Feb-2025

Previous Close

4.22

Open

4.18

Day's Range

3.82 - 4.18

Year Range

2.12 - 8.975

Trading Volume

1,661,755

Price Change Highlight

1 Day Change

-5.69%

5 Day Change

-2.93%

1 Month Change

-29.43%

3 Month Change

-46.51%

6 Month Change

-22.72%

Ytd Change

-1.97%

1 Year Change

77.68%

3 Year Change

388.34%

5 Year Change

165.33%

10 Year Change

165.33%

Max Change

165.33%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment